Raymond James last night initiated coverage of Insmed (INSM) with an Outperform rating and $200 price target The firm believes Brinsupri’s early launch performance has “materially de-risked the story” and positions Insmed among the strongest inflammation and immunology launches ever. Brinsupri is addressing a large, underserved market with limited near-term competition, the analyst tells investors in a research note. Raymond James believes the drug is still early in its growth curve.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed initiated with an Outperform at Raymond James
- Insmed price target lowered to $202 from $206 at Mizuho
- Reallocating Capital Beyond HS: Supporting a Buy Rating on Insmed’s Diversified Next‑Generation Pipeline
- Insmed price target lowered to $212 from $213 at BofA
- Insmed’s phase 2 a ‘clearing event’, says Roth Capital